Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic and environmental risk factors for oral anticoagulant overdose.

European journal of clinical pharmacology - 1 Mar 2003

Verstuyft C, Robert A, Morin S, Loriot M A, Flahault A, Beaune P, Funck-Brentano C, Jaillon P, Becquemont L

Abstract excerpt

BACKGROUND: Cytochrome P450 2C9 (CYP2C9) allelic variant carriers have been shown to experience hyper-responsiveness to small doses of oral anticoagulants (OAs) (warfarin or acenocoumarol) and a higher bleeding rate. OBJECTIVES: To determine the relative frequencies of different risk factors for OA overdose including diet, concomitant diseases, drug interactions, recent increment of OA dose and CYP2C9 genetic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Anticoagulants

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C9

Share to Drug Interactions

Share to Hemorrhage

Share to Inpatients

Share to International Normalized Ratio

Share to Vitamin K

Source

Identifiers

PMID: 12634980
DOI: 10.1007/s00228-002-0538-2

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic and environmental risk factors for oral anticoagulant overdose.PMID 12634980Read ↗

VKORC1 and CYP2C9 genotypes and acenocoumarol anticoagulation status: interaction between both genotypes affects overanticoagulation.Semantic proximity Read ↗

Impact of CYP2C9 polymorphisms on the vulnerability to pharmacokinetic drug-drug interactions during acenocoumarol treatment.Semantic proximity Read ↗

[The c.-1639g > A polymorphism of the VKORC1 gene and his influence on the therapeutic response during oral anticoagulants use].Semantic proximity Read ↗

CYP2C9 and VKORC1 in therapeutic dosing and safety of acenocoumarol treatment: implication for clinical practice in Hungary.Semantic proximity Read ↗

Pharmacogenetics of oral anticoagulantsSemantic proximity Read ↗

Effects of CYP2C9 and VKORC1 on INR variations and dose requirements during initial phase of anticoagulant therapy.Semantic proximity Read ↗

Long-term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users.Semantic proximity Read ↗

Cytochrome P450 2C9 polymorphism and acenocoumarol therapy.Semantic proximity Read ↗

The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon.Semantic proximity Read ↗

Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine?Semantic proximity Read ↗

Several-fold increase in risk of overanticoagulation by CYP2C9 mutations.Semantic proximity Read ↗

Genotypes associated with reduced activity of VKORC1 and CYP2C9 and their modification of acenocoumarol anticoagulation during the initial treatment period.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.